淋巴细胞与单核细胞比值和血小板与单核细胞比值所构建的新预后模型在外周T细胞淋巴瘤中的价值

The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma.

作者信息

Zhang Yan, Shi Yuanfei, Shen Huafei, Shou Lihong, Fang Qiu, Zheng Xiaolong, Zhu Mingyu, Huang Xin, Huang Jiansong, Li Li, Zhou De, Zhu Lixia, Zhu Jingjing, Ye Xiujin, Jin Jie, Xie Wanzhuo

机构信息

Department of Hematology, College of Medicine, Affiliated Huzhou Hospital, Zhejiang University, No. 1558 North Third Ring Road, Huzhou, 313000, Zhejiang, China.

Department of Hematology, College of Medicine, the First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.

出版信息

Cancer Cell Int. 2021 Oct 29;21(1):573. doi: 10.1186/s12935-021-02275-2.

Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Although a few prognostic models of PTCL have been established in retrospective studies, some high-risk patients still can not be screened out. Therefor we retrospectively studied 347 newly diagnosed PTCL patients and assessed the prognostic role of lymphocyte-monocyte ratio (LMR) and platelet-monocyte ratio (PMR) in the complete response (CR) and survival of PTCL patients. Patients with LMR ≤ 1.68 and PMR ≤ 300 achieved a lower CR rate and a poor survival. In multivariate analysis, LMR ≤ 1.68 (HR = 1.751, 95% CI 1.158-2.647, p < 0.05) and PMR ≤ 300 (HR = 1.762, 95% CI 1.201-2.586, p < 0.05) were independently associated with short survival. On this basis, a new prognostic model of PTCL was established to screen out high-risk patients. In our "Peripheral Blood Score (PBS)" model, three groups were identified at low risk (178 patients, 51.3%, score 0), intermediate risk (85 patients, 24.5%, score 1), and high risk (84 patients, 24.2%, score 2), having a 1-year OS of 86%, 55.3% and 22.6% (p < 0.05), and a 3-year OS of 43.4%, 20% and 13.1% (p < 0.05), respectively. Optimal strategies for identifying high-risk patients with PTCL are urgently needed. Our new PBS model is simple, inexpensive and widely available to screen out the high risk patients.

外周T细胞淋巴瘤（PTCL）是一组起源于胸腺后T细胞或成熟自然杀伤（NK）细胞的淋巴增殖性肿瘤。它表现出高度侵袭性的临床行为、对传统化疗的耐药性以及较差的预后。尽管在回顾性研究中已经建立了一些PTCL的预后模型，但仍有一些高危患者无法被筛选出来。因此，我们对347例新诊断的PTCL患者进行了回顾性研究，评估淋巴细胞单核细胞比值（LMR）和血小板单核细胞比值（PMR）在PTCL患者完全缓解（CR）和生存中的预后作用。LMR≤1.68且PMR≤300的患者CR率较低且生存较差。在多变量分析中，LMR≤1.68（HR = 1.751，95%CI 1.158 - 2.647，p < 0.05）和PMR≤300（HR = 1.762，95%CI 1.201 - 2.586，p < 0.05）与生存期短独立相关。在此基础上，建立了一种新的PTCL预后模型以筛选高危患者。在我们的“外周血评分（PBS）”模型中，确定了低风险（178例患者，51.3%，评分0）、中风险（85例患者，24.5%，评分1）和高风险（84例患者，24.2%，评分2）三组，其1年总生存率分别为86%、55.3%和22.6%（p < 0.05），3年总生存率分别为43.4%、20%和13.1%（p < 0.05）。迫切需要识别PTCL高危患者的最佳策略。我们新的PBS模型简单、廉价且广泛适用，可筛选出高危患者。